Posted by kinasepro on January 5, 2007
Making some bold claims, Innovive gets orphan status for INNO-406 / NS-187
This entry was posted on January 5, 2007 at 7:31 pm and is filed under bcr abl, clinical, lyn.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
A second generation of a successful drug does not necessarily has to be from the same company – look what Sepracor did.
Also, it often takes a very small change to get a superior PK or selectivity profile.
No doubt, and my hat’s off to Nippon Shinyaku Co, but that just strikes me as the kind of thing you make and claim on the first, or at least the second go round…
Small change, gives big difference. It happens in Kinase drug discovery. To get this small change, they might have spent years of work!!!! No surprise.
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.